Site Map

Reglan News

Neurocrine Tardive Dyskinesia Drug Enters Phase II of Clinical Trials

On Sept. 19, 2011, Neurocrine Biosciences Inc. announced that phase II clinical trial of a new drug to treat tardive dyskinesia... read more

Reglan Linked to Tardive Dyskinesia, Says FDA

Patients treated with Reglan® should be aware of the risk of tardive dyskinesia, and should visit their doctors right away if... read more

FDA Petitioned to Change Regulations for Generic Drug Makers

The consumer advocacy group, Public Citizen, is urging the FDA to revise regulations that prevent generic drug makers from changing warning... read more

Tardive Dyskinesia

Reglan®

Reglan® Lawsuit

Pages

ATTORNEY ADVERTISEMENT: Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional.

Flood Law Group, LLP | 1101 Pennsylvania Avenue, Suite 600 | Washington, DC 20004